Alzamend Neuro Stock (ALZN) Rockets 145% on Study Update
Stock Surge: Alzamend Neuro's stock (ALZN) soared 143.98% after announcing the dosing of the first patient in its Phase II clinical study for AL001, aimed at improving lithium delivery to the brain for various mental health conditions.
Analyst Outlook: Only one analyst has recently covered ALZN, giving it a Buy rating with a $20 price target, indicating a potential upside of 502.41% despite the stock's significant year-to-date and year-over-year declines.
Trade with 70% Backtested Accuracy
Analyst Views on ALZN
About ALZN
About the author
Alzamend Neuro Completes Clinical Phase of Phase II Trial for AL001 "Lithium in Brain" at Massachusetts General Hospital
Clinical Trial Completion: Alzamend Neuro has completed the clinical portion of its Phase II trial for AL001, a novel lithium-delivery system, aimed at improving treatment for Alzheimer's, bipolar disorder, major depressive disorder, and PTSD.
Innovative Imaging Technology: The trial utilized a unique head coil technology for high-resolution lithium imaging, allowing for precise quantification of lithium in the brain, which may lead to better therapeutic efficacy and reduced side effects compared to conventional lithium salts.
Potential for Improved Safety: AL001 is designed to deliver lithium effectively while minimizing systemic exposure, potentially eliminating the need for therapeutic drug monitoring (TDM) and reducing risks of kidney and thyroid complications associated with traditional lithium treatments.
Future Developments: Alzamend plans to report topline data in the first quarter of 2026 and aims to initiate further Phase II clinical trials next year, building on the promising results of AL001's safety and efficacy profile.
EXCLUSIVE: Alzamend Completes Clinical Phase of AL001 Study In Healthy Volunteers
Clinical Study Completion: Alzamend Neuro has completed the clinical portion of its first Phase 2 study of AL001, a novel oral therapeutic for Alzheimer's and other disorders, with topline data expected in early 2026.
Innovative Drug Delivery: AL001 aims to provide a safer lithium delivery system, potentially reducing systemic side effects and eliminating the need for frequent therapeutic drug monitoring, which is a challenge with traditional lithium salts.
Imaging Technology Utilization: The study employed advanced imaging technology to accurately quantify lithium in the brain, helping to establish optimal dosing for specific diseases.
Secondary Drug Candidate: Alzamend is also developing ALZN002, an immunotherapy targeting amyloid-beta proteins in Alzheimer's patients, with a Phase 1/2A trial already initiated to assess its safety and efficacy.
Hewlett Packard Enterprise Set to Surge by 33%? Check Out 10 Leading Analyst Predictions for Thursday
Analyst Upgrades and Downgrades: Several Wall Street analysts have adjusted their price targets for various companies, with notable changes including I-Mab's target raised from $5 to $6 and Alzamend Neuro's target cut from $180 to $45.
Company Performance Ratings: Analysts maintained Buy ratings for I-Mab, DRDGOLD Limited, and The TJX Companies, while also upgrading Hewlett Packard Enterprise from Equal-Weight to Overweight.
Price Target Adjustments: Other significant adjustments include HC Wainwright raising DRDGOLD's target to $18.75, Susquehanna increasing Analog Devices' target to $300, and Piper Sandler reducing Civitas Resources' target to $52.
Current Stock Prices: As of Wednesday, I-Mab closed at $4.52, Alzamend Neuro at $2.26, and Lowe's at $257.14, reflecting the market's response to these analyst ratings and price target changes.
Ascendiant Capital Reaffirms Buy Rating on Alzamend Neuro, Adjusts Price Target to $45
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing strategies and intelligence.
Market Winning Tool: Traders utilize Benzinga Pro's resources to enhance their trading success in the stock market.
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium
Alzamend Neuro's Presentation: Alzamend Neuro will present research on its novel lithium-delivery system, AL001, at the Military Health System Research Symposium, focusing on its potential benefits for treating PTSD and other mental health disorders in military personnel.
Study Objectives and Innovations: The study aims to compare lithium brain-to-plasma exposure between AL001 and traditional lithium carbonate, with the goal of improving treatment efficacy while minimizing side effects, thereby enhancing safety for patients.
Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule
Funding Announcement: Alzamend Neuro, Inc. has successfully completed a $5 million private placement to support its clinical trials for treatments targeting Alzheimer's disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder.
Clinical Trials Update: The funds will be used for five Phase II clinical trials, with the first trial for healthy subjects already initiated in May 2025, and additional trials for various conditions expected to commence by the end of 2025.
Alzamend Neuro Completes Clinical Phase of Phase II Trial for AL001 "Lithium in Brain" at Massachusetts General Hospital
Clinical Trial Completion: Alzamend Neuro has completed the clinical portion of its Phase II trial for AL001, a novel lithium-delivery system, aimed at improving treatment for Alzheimer's, bipolar disorder, major depressive disorder, and PTSD.
Innovative Imaging Technology: The trial utilized a unique head coil technology for high-resolution lithium imaging, allowing for precise quantification of lithium in the brain, which may lead to better therapeutic efficacy and reduced side effects compared to conventional lithium salts.
Potential for Improved Safety: AL001 is designed to deliver lithium effectively while minimizing systemic exposure, potentially eliminating the need for therapeutic drug monitoring (TDM) and reducing risks of kidney and thyroid complications associated with traditional lithium treatments.
Future Developments: Alzamend plans to report topline data in the first quarter of 2026 and aims to initiate further Phase II clinical trials next year, building on the promising results of AL001's safety and efficacy profile.
EXCLUSIVE: Alzamend Completes Clinical Phase of AL001 Study In Healthy Volunteers
Clinical Study Completion: Alzamend Neuro has completed the clinical portion of its first Phase 2 study of AL001, a novel oral therapeutic for Alzheimer's and other disorders, with topline data expected in early 2026.
Innovative Drug Delivery: AL001 aims to provide a safer lithium delivery system, potentially reducing systemic side effects and eliminating the need for frequent therapeutic drug monitoring, which is a challenge with traditional lithium salts.
Imaging Technology Utilization: The study employed advanced imaging technology to accurately quantify lithium in the brain, helping to establish optimal dosing for specific diseases.
Secondary Drug Candidate: Alzamend is also developing ALZN002, an immunotherapy targeting amyloid-beta proteins in Alzheimer's patients, with a Phase 1/2A trial already initiated to assess its safety and efficacy.
Hewlett Packard Enterprise Set to Surge by 33%? Check Out 10 Leading Analyst Predictions for Thursday
Analyst Upgrades and Downgrades: Several Wall Street analysts have adjusted their price targets for various companies, with notable changes including I-Mab's target raised from $5 to $6 and Alzamend Neuro's target cut from $180 to $45.
Company Performance Ratings: Analysts maintained Buy ratings for I-Mab, DRDGOLD Limited, and The TJX Companies, while also upgrading Hewlett Packard Enterprise from Equal-Weight to Overweight.
Price Target Adjustments: Other significant adjustments include HC Wainwright raising DRDGOLD's target to $18.75, Susquehanna increasing Analog Devices' target to $300, and Piper Sandler reducing Civitas Resources' target to $52.
Current Stock Prices: As of Wednesday, I-Mab closed at $4.52, Alzamend Neuro at $2.26, and Lowe's at $257.14, reflecting the market's response to these analyst ratings and price target changes.
Ascendiant Capital Reaffirms Buy Rating on Alzamend Neuro, Adjusts Price Target to $45
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing strategies and intelligence.
Market Winning Tool: Traders utilize Benzinga Pro's resources to enhance their trading success in the stock market.
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium
Alzamend Neuro's Presentation: Alzamend Neuro will present research on its novel lithium-delivery system, AL001, at the Military Health System Research Symposium, focusing on its potential benefits for treating PTSD and other mental health disorders in military personnel.
Study Objectives and Innovations: The study aims to compare lithium brain-to-plasma exposure between AL001 and traditional lithium carbonate, with the goal of improving treatment efficacy while minimizing side effects, thereby enhancing safety for patients.
Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule
Funding Announcement: Alzamend Neuro, Inc. has successfully completed a $5 million private placement to support its clinical trials for treatments targeting Alzheimer's disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder.
Clinical Trials Update: The funds will be used for five Phase II clinical trials, with the first trial for healthy subjects already initiated in May 2025, and additional trials for various conditions expected to commence by the end of 2025.
